trans-Resveratrol, an extract of red wine, inhibits human eosinophil activation and degranulation.
OBJECTIVE
trans-Resveratrol, a non-flavonoid polyphenol found abundantly in red wine possesses antiproliferative and anti-inflammatory activity in various inflammatory disease conditions. However, the effect of trans-resveratrol on eosinophil activation in relation to allergy has not been investigated.


METHODS
Human eosinophils were isolated and purified from whole blood and incubated for 16 h with trans-resveratrol. Eosinophil chemotaxis, activation and degranulation, and apoptosis were investigated. The effect of trans-resveratrol on the inhibition of p38 and ERK1/2 activation was examined.


RESULTS
Treatment of human eosinophils with trans-resveratrol at concentrations <100 microM for 16 h did not induce eosinophil apoptosis. Similar results were seen after 24 h and 48 h incubations. trans-Resveratrol (<100 microM) significantly inhibited eosinophil peroxidase release after activation with IL-5 (IC(50)=2.9+/-0.9 microM) or C5a (IC(50)=3.9+/-0.5 microM) after 5 min priming with cytochalasin B (CB). Similarly, the production of leukotriene C4 after stimulation with calcium ionophore, and eosinophil chemotaxis in response to eotaxin, as well as CD11b upregulation and CD62 L shedding was also significantly reduced by trans-resveratrol, at concentrations above 5 microM. All the activators induced p38 and ERK1/2 phosphorylation maximal at 2 min of activation. trans-Resveratrol potently inhibited p38 and ERK1/2 activation after calcium ionophore and CB and C5a activation.


CONCLUSIONS
trans-Resveratrol is effective at inhibiting human eosinophil activation and degranulation at concentrations <100 microM, while not inducing apoptosis. This potent anti-inflammatory activity of trans-resveratrol and possibly its metabolites on eosinophils may be worth investigating for the treatment of eosinophil-related allergic diseases.
Tan
Y
Y
Inflammation and Cancer Laboratory, Department of Physiology and NUS Immunology Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Lim
L H K
LH
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015550:Cell Degranulation / Q000187:drug effects*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D047209:Eosinophil Peroxidase / Q000187:drug effects / Q000378:metabolism; D004804:Eosinophils / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D020128:Inhibitory Concentration 50; D017997:Leukotriene C4 / Q000378:metabolism; D019950:Mitogen-Activated Protein Kinase 1 / Q000187:drug effects / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000187:drug effects / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors; D014920:Wine; D048051:p38 Mitogen-Activated Protein Kinases / Q000187:drug effects / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D013267:Stilbenes; D017997:Leukotriene C4; D047209:Eosinophil Peroxidase; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D048051:p38 Mitogen-Activated Protein Kinases; D000077185:Resveratrol
J Allergy Clin Immunol. 2001 Oct;108(4):503-8
11590372
Am Rev Respir Dis. 1991 Nov;144(5):1053-7
1659268
J Leukoc Biol. 1994 May;55(5):662-75
8182345
Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):953-7
14578128
J Allergy Clin Immunol. 1985 Oct;76(4):595-604
4056248
FASEB J. 2005 May;19(7):840-1
15734790
Int Immunopharmacol. 2003 Jun;3(6):845-52
12781701
Br Med Bull. 2000;56(4):985-1003
11359633
Am J Respir Cell Mol Biol. 2000 Jun;22(6):693-701
10837366
Blood. 2000 Mar 15;95(6):1911-7
10706854
N Engl J Med. 1990 Oct 11;323(15):1033-9
2215562
J Immunol. 2000 Aug 15;165(4):2198-204
10925307
J Allergy Clin Immunol. 1988 Apr;81(4):711-7
3356850
Br J Pharmacol. 2006 Apr;147(8):873-85
16474422
J Immunol. 1999 Aug 1;163(3):1611-8
10415066
Leukemia. 2001 Nov;15(11):1735-42
11681415
J Endocrinol. 2003 Jul;178(1):37-43
12844334
Br J Pharmacol. 1998 Apr;123(8):1691-9
9605577
J Exp Med. 1995 May 1;181(5):1827-34
7722458
Clin Exp Immunol. 2000 Apr;120(1):12-21
10759758
J Immunol. 2001 May 1;166(9):5763-72
11313420
J Allergy Clin Immunol. 1987 Mar;79(3):496-504
3029204
Lancet. 2000 Dec 23-30;356(9248):2144-8
11191542
J Pharmacol Exp Ther. 2002 Jul;302(1):369-73
12065739
J Immunol. 1989 Oct 1;143(7):2311-6
2506282
Proc Natl Acad Sci U S A. 1983 Dec;80(24):7626-30
6324182
Int J Mol Med. 2005 Feb;15(2):337-52
15647852
Drug Metab Dispos. 2004 Dec;32(12):1377-82
15333514
Eur J Cardiovasc Prev Rehabil. 2005 Dec;12(6):596-600
16319551
Adv Immunol. 1986;39:177-253
3538819
Physiol Res. 2003;52(5):555-62
14535830
Trends Pharmacol Sci. 1995 Sep;16(9):304-9
7482995
Expert Opin Investig Drugs. 2006 Oct;15(10):1191-200
16989596
J Clin Endocrinol Metab. 2002 Mar;87(3):1223-32
11889192
Am J Physiol Lung Cell Mol Physiol. 2004 Oct;287(4):L774-83
15180920
Clin Biochem. 2003 Feb;36(1):79-87
12554065
Cancer Lett. 1999 Jun 1;140(1-2):1-10
10403535
FASEB J. 2003 Nov;17(14):1975-85
14597667
Eur J Clin Invest. 2003 Sep;33(9):818-23
12925042